Rankings
▼
Calendar
ACLX
Arcellx, Inc.
$7B
Q3 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$5M
-81.0% YoY
Gross Profit
-$30M
-609.0% margin
Operating Income
-$62M
-1248.3% margin
Net Income
-$56M
-1127.1% margin
EPS (Diluted)
$-0.99
QoQ Revenue Growth
-34.5%
Cash Flow
Operating Cash Flow
-$49M
Free Cash Flow
-$50M
Stock-Based Comp.
$18M
Balance Sheet
Total Assets
$656M
Total Liabilities
$215M
Stockholders' Equity
$441M
Cash & Equivalents
$79M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$5M
$26M
-81.0%
Gross Profit
-$30M
$26M
-215.8%
Operating Income
-$62M
-$34M
-83.8%
Net Income
-$56M
-$26M
-115.6%
← FY 2025
All Quarters
Q4 2025 →
ACLX Q3 2025 Earnings — Arcellx, Inc. Revenue & Financial Results | Market Cap Arena